BACKGROUND: We investigated the role of antibody responses as potential mechanism for the cross-protective vaccine-efficacies (VE) observed from randomized clinical trials of the HPV16/18 bivalent vaccine. Results HPV31 cases had lower HPV16 antibody levels than controls (OR 4th quartile compared with 1st quartile = 0.63; 95%CI: 0.36-1.08; p-trend = 0.03). HPV31 cases were also less likely to have detectable HPV31 neutralization, and HPV16 avidity than controls. No statistically significant differences by HPV18 antibody or HPV45 neutralization were observed among HPV45 cases and controls. Protection against HPV58 was not associated with any of the markers, confirming the specificity of our findings. METHODS: Samples are from three-dose HPV vaccine recipients from the Costa Rica HPV16/18 vaccine trial. Women with a new HPV31, HPV45, or HPV58 infections over four years of follow-up were compared with randomly selected control women--with no new infection with HPV31/45/58--with respect to HPV16 and HPV18 antibody, HPV31, HPV45, and HPV58 neutralization, and HPV16 avidity. CONCLUSIONS: High HPV16 levels and avidity, and the ability to neutralize HPV31 were associated with protection against newly detected HPV31 infections, suggesting that the partial VE demonstrated for HPV31 is likely to be mediated at least in part through antibodies induced by HPV16/18 vaccination.
RCT Entities:
BACKGROUND: We investigated the role of antibody responses as potential mechanism for the cross-protective vaccine-efficacies (VE) observed from randomized clinical trials of the HPV16/18 bivalent vaccine. Results HPV31 cases had lower HPV16 antibody levels than controls (OR 4th quartile compared with 1st quartile = 0.63; 95%CI: 0.36-1.08; p-trend = 0.03). HPV31 cases were also less likely to have detectable HPV31 neutralization, and HPV16 avidity than controls. No statistically significant differences by HPV18 antibody or HPV45 neutralization were observed among HPV45 cases and controls. Protection against HPV58 was not associated with any of the markers, confirming the specificity of our findings. METHODS: Samples are from three-dose HPV vaccine recipients from the Costa Rica HPV16/18 vaccine trial. Women with a new HPV31, HPV45, or HPV58 infections over four years of follow-up were compared with randomly selected control women--with no new infection with HPV31/45/58--with respect to HPV16 and HPV18 antibody, HPV31, HPV45, and HPV58 neutralization, and HPV16 avidity. CONCLUSIONS: High HPV16 levels and avidity, and the ability to neutralize HPV31 were associated with protection against newly detected HPV31 infections, suggesting that the partial VE demonstrated for HPV31 is likely to be mediated at least in part through antibodies induced by HPV16/18 vaccination.
Entities:
Keywords:
HPV vaccine; cross-protection; humoral; immune response; mechanisms for protection
Authors: Troy J Kemp; Alfonso García-Piñeres; Roni T Falk; Sylviane Poncelet; Francis Dessy; Sandra L Giannini; Ana Cecilia Rodriguez; Carolina Porras; Rolando Herrero; Allan Hildesheim; Ligia A Pinto Journal: Vaccine Date: 2008-05-19 Impact factor: 3.641
Authors: B Kleter; L J van Doorn; L Schrauwen; A Molijn; S Sastrowijoto; J ter Schegget; J Lindeman; B ter Harmsel; M Burger; W Quint Journal: J Clin Microbiol Date: 1999-08 Impact factor: 5.948
Authors: J A Suzich; S J Ghim; F J Palmer-Hill; W I White; J K Tamura; J A Bell; J A Newsome; A B Jenson; R Schlegel Journal: Proc Natl Acad Sci U S A Date: 1995-12-05 Impact factor: 11.205
Authors: Judith F Smith; Michelle Brownlow; Martha Brown; Rose Kowalski; Mark T Esser; Wanda Ruiz; Eliav Barr; Darron R Brown; Janine T Bryan Journal: Hum Vaccin Date: 2007-02-24
Authors: Rolando Herrero; Allan Hildesheim; Ana C Rodríguez; Sholom Wacholder; Concepción Bratti; Diane Solomon; Paula González; Carolina Porras; Silvia Jiménez; Diego Guillen; Jorge Morales; Mario Alfaro; Jean Cyr; Kerrygrace Morrisey; Yenory Estrada; Bernal Cortés; Lidia Ana Morera; Enrique Freer; John Schussler; John Schiller; Douglas Lowy; Mark Schiffman Journal: Vaccine Date: 2008-07-18 Impact factor: 3.641
Authors: F Breitburd; R Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; G Orth; J T Schiller; D R Lowy Journal: J Virol Date: 1995-06 Impact factor: 5.103
Authors: Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Cosette M Wheeler; Song-Nan Chow; Dan L Apter; Henry C Kitchener; Xavier Castellsague; Newton S de Carvalho; S Rachel Skinner; Diane M Harper; James A Hedrick; Unnop Jaisamrarn; Genara Am Limson; Marc Dionne; Wim Quint; Bart Spiessens; Pascal Peeters; Frank Struyf; Susan L Wieting; Matti O Lehtinen; Gary Dubin Journal: Lancet Date: 2007-06-30 Impact factor: 79.321
Authors: Mahboobeh Safaeian; Joshua N Sampson; Yuanji Pan; Carolina Porras; Troy J Kemp; Rolando Herrero; Wim Quint; Leen Jan van Doorn; John Schussler; Douglas R Lowy; John Schiller; Mark T Schiffman; Ana Cecilia Rodriguez; Mitchell H Gail; Allan Hildesheim; Paula Gonzalez; Ligia A Pinto; Aimée R Kreimer Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Douglas M Herrin; Emily E Coates; Pamela J Costner; Troy J Kemp; Martha C Nason; Kapil K Saharia; Yuanji Pan; Uzma N Sarwar; Lasonji Holman; Galina Yamshchikov; Richard A Koup; Yuk Ying S Pang; Robert A Seder; John T Schiller; Barney S Graham; Ligia A Pinto; Julie E Ledgerwood Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Hilary A Robbins; Tim Waterboer; Carolina Porras; Troy J Kemp; Michael Pawlita; Ana Cecilia Rodriguez; Sholom Wacholder; Paula Gonzalez; John T Schiller; Douglas R Lowy; Mark Esser; Katie Matys; Sylviane Poncelet; Rolando Herrero; Allan Hildesheim; Ligia A Pinto; Mahboobeh Safaeian Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows Journal: J Virol Date: 2015-05-20 Impact factor: 5.103
Authors: Lars Toft; Martin Tolstrup; Martin Müller; Peter Sehr; Jesper Bonde; Merete Storgaard; Lars Østergaard; Ole S Søgaard Journal: Hum Vaccin Immunother Date: 2014-02-19 Impact factor: 3.452
Authors: Robbie Woods; Esther M O'Regan; Susan Kennedy; Cara Martin; John J O'Leary; Conrad Timon Journal: World J Clin Cases Date: 2014-06-16 Impact factor: 1.337
Authors: Ariana Harari; Zigui Chen; Ana Cecilia Rodríguez; Allan Hildesheim; Carolina Porras; Rolando Herrero; Sholom Wacholder; Orestis A Panagiotou; Brian Befano; Robert D Burk; Mark Schiffman Journal: J Infect Dis Date: 2015-10-30 Impact factor: 5.226